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Tumor-Specific Human CD4 Regulatory T Cells
and Their Ligands: Implications for Immunotherapy
self-tolerance (Roncarolo and Levings, 2000; Sakaguchi
et al., 2001; Shevach, 2002). Their induction of self-toler-
ance extends to autoimmune diseases, allergy, and
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transplantation and antitumor immunity (Sakaguchi et1The Center for Cell and Gene Therapy and
al., 2001; Shevach, 2000). Besides naturally occurringDepartment of Immunology
CD4 CD25 Treg cells, other CD4 Treg cells includeBaylor College of Medicine
Tr-1 cells secreting IFN- and IL-10, and Th3 cells se-Houston, Texas 77030
creting high levels of TGF-, IL-4, and IL-10 (Francois2 Laboratory of Immunology
Bach, 2003; Roncarolo and Levings, 2000; Weiner,National Institute of Allergy and
2001). Although expression of CD25 on T cells has beenInfectious Diseases
used as a useful marker of Treg cells, its expression isNational Institutes of Health
not necessarily associated with Treg cell function in thatBethesda, Maryland 20892
it is also expressed by activated, nonregulatory effector
lymphocytes. Other molecules, including the TNF family
molecule GITR and cytotoxic T lymphocyte antigen-4Summary
(CTLA4) may serve as markers for Treg cells (Sakaguchi
et al., 2001; Wood and Sakaguchi, 2003). Recently, sev-Regulatory T cells play an important role in the mainte-
eral groups reported that foxp3 may serve as a potentialnance of immunological self-tolerance by suppressing
marker of CD4 Treg cells in mice (Fontenot et al., 2003;immune responses against autoimmune diseases and
Hori et al., 2003; Khattri et al., 2003), but it is not clearcancer. Little is known, however, about the nature of
whether the finding also applies to human CD4 Tregthe physiological target antigens for CD4 regulatory
cells. Therefore, Treg cells must be defined primarilyT (Treg) cells. Here we report the identification of the
according to their immunosuppressive function (vonLAGE1 protein as a ligand for tumor-specific CD4
Herrath and Harrison, 2003). They inhibit other immuneTreg cell clones generated from the tumor-infiltrating
cell functions either directly through cell-cell contactlymphocytes (TILs) of cancer patients. Phenotypic and
or indirectly through the secretion of anti-inflammatoryfunctional analyses demonstrated that they were anti-
mediators such as IL-10, TGF-, or IL-4 (Levings et al.,gen-specific CD4 Treg cells expressing CD25 and
2002a; Shevach, 2002). Treg cells are demonstratedGITR molecules and possessing suppressive activity
most convincingly by their ability to inhibit autoimmuneon the proliferative response of naive CD4 T cells to
disease development of transplant rejection in animalanti-CD3 antibody stimulation. Ligand-specific activa-
models, after de novo induction in vivo or after passivetion and cell-cell contact were required for TIL102 Treg
cotransfer with effector cells into suitable hosts (voncells to exert suppressive activity on CD4 effector
Herrath and Harrison, 2003).cells. These findings suggest that the presence of tu-
While most studies have been focused on the role ofmor-specific CD4 Treg cells at tumor sites may have
Treg cells in the prevention of various organ-specifica profound effect on the inhibition of T cell responses
autoimmune diseases (Sakaguchi et al., 1995; Shevach,against cancer.
2000), several recent studies report an increased fre-
quency of CD4 Treg cells in cancer patients (LiyanageIntroduction
et al., 2002; Woo et al., 2001). In animal models, removal
of CD4CD25 Treg cells enhances antitumor immune
CD4 effector and regulatory T cells recognize peptides
responses (Shimizu et al., 1999; Sutmuller et al., 2001),
presented by MHC class II molecules but play distinctly
implying that these cells suppress immune responses
different roles in regulating host immune responses against cancer cells. However, very little is known about
against cancer and other diseases (Germain, 1994; Ro- the physiological target antigens recognized by CD4
senberg, 2001; Sakaguchi et al., 2001; Shevach, 2002). Treg cells in such settings. Our current knowledge of
CD4 effector (helper) T cells are required for the priming the antigen specificity of CD4 Treg cells has come
and maintenance of CD8 T cells, thus enhancing the largely from studies with antigen-specific TCR trans-
overall immune response (Houghton et al., 2001; Wang, genic animals (Apostolou et al., 2002; Curotto de Lafaille
2001). Recently, CD4 T cells were shown to be required and Lafaille, 2002; Hori et al., 2002; Maloy and Powrie,
for the subsequent expansion of memory CD8 T cells 2001; Shevach, 2002). Because bulk CD4 CD25 T cell
(Janssen et al., 2003; Shedlock and Shen, 2003; Sun populations may display very diverse specificities for
and Bevan, 2003). Thus, identification of MHC class II- autoantigens (tissue-specific self-antigens) and tumor
restricted tumor antigens capable of stimulating CD4 antigens, it has been difficult to identify the physiological
T cell responses is a critical step in the development of ligands recognized by antigen-specific CD4 Treg cells.
effective cancer vaccines (Wang, 2002). During the course of our work on MHC class II-restricted
Paradoxically, CD4 T regulatory (Treg) cells can pro- tumor antigens, we established tumor-specific CD4 T cell
foundly suppress host immune responses and induce clones from tumor-infiltrating lymphocytes (TILs) directly
from fresh melanoma tumor samples. These CD4 T cell
clones were found to function as CD4 Treg cells. In*Correspondence: rongfuw@bcm.tmc.edu
3These authors contributed equally to this work. this report, we describe the generation and character-
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Figure 1. Specific Recognition of Tumor
Cells by CD4 TIL102 T Cells
(A) Recognition of HLA-DR13-positive
M102mel and 1495mel cells, but not EBV-B
cell lines and allogeneic melanoma cell lines
or 293-derived cell lines. T cell recognition
was evaluated by IFN- release from CD4
TIL102-C4 cells.
(B) HLA restriction of T cell recognition. CD4
TIL102-C4 cells were cocultured with autolo-
gous M102mel cells in the presence or absence
of various anti-HLA antibodies. GM-CSF re-
lease was determined after an 18 hr incuba-
tion. T cell recognition of M102mel was spe-
cifically blocked by an anti-DR antibody, but
not by anti-HLA class I, anti-HLA-DQ, or anti-
DP antibodies.
(C) T cell recognition of HLA-DR13-positive
LCL cells pulsed with tumor lysates. TIL102-
C4 cells were cocultured with 586EBV (HLA-
DR1), 1359EBV (HLA-DR3 and -DR4),
LCL-7 cells (HLA-DR13) previously pulsed
with or without tumor lysates of M102 over-
night. IFN- release from CD4 TIL102-C4
cells was measured in culture supernatants
by ELISA. Similar results were obtained with
the other 12 T cell clones.
ization of tumor-specific CD4 Treg cells and identifica- obtained with other T cell clones (data not shown). T cells
responded to both HLA-DR13 M102 and 1495mel tu-tion of their natural ligands. Using these antigen-specific
cells, we also show that cell-cell contact is required for mor cell lines, but not to DR13 EBV-transformed B cells
or DR13 cell lines. T cell reactivity against M102 tumorTreg cell mediated immune suppression.
cells could be specifically blocked by a monoclonal anti-
body against HLA-DR, but not by one against HLA-DQ,Results
HLA-DP, or MHC class I molecules (Figure 1B). To further
determine the restriction element, we tested whetherGeneration of Tumor-Specific CD4 T Cell Clones
A tumor-reactive TIL line (TIL102) was first established CD4 T cell clones could recognize DR3-positive or
DR13-positive EBV-transformed B cells pulsed withfrom a fresh melanoma sample. After depletion of CD8
T cells with a bead-coated anti-CD8 antibody, we estab- M102 tumor lysates. As shown in Figure 1C, CD4 T cells
responded to DR13-positive LCL-7 cells pulsed withlished CD4 T cell lines that recognized an autologous
tumor cell line (M102) generated from the same tumor tumor cell lysates but recognize neither DR13-positve
LCL-7 cells alone nor DR3-positive 1359EBV cellssample. To obtain tumor-reactive CD4 T cell clones,
we cloned T cells (0.3 cell/well) by a limiting dilution pulsed with the same tumor cell lysates. These studies
suggest that CD4 T cells recognize a tumor antigen inmethod in culture medium containing irradiated PBMCs
(5  104 cells per well in a 96-well plate), anti-CD3, anti- the context of an HLA-DR13 molecule.
CD28, and 30 IU/ml of IL-2 (Wang et al., 2002). After 14
days, the growing T cell clones were screened for tumor Identification of a Gene Encoding a Nonmutated
LAGE1 Proteinreactivity based on the secretion of GM-CSF, a cytokine
released by different types of antigen-specific T cells, We next attempted to identify the target antigen recog-
nized by tumor-specific CD4 T cells. In previous stud-including CD4 Th1, Th2, and CD8 T cells. Thirteen
tumor-reactive T cell clones were generated and further ies, we devised a genetic targeting expression system
and used it to identify several MHC class II-restrictedexpanded. To determine the antigen specificity of T cell
clones, we tested these T clones against various target tumor antigens (Wang et al., 1999a). For this system,
we generated 293ECIIDR13 cells expressing Ii, DMA,cells, including HLA-DR3 and DR13 M102 tumor cells
(the HLA typing for M102 is HLA-DR3 and -DR13). Repre- DMB, and DR13 molecules as antigen-presenting cells
for efficiently processing and presenting antigens tosentative data for one such CD4 T cell clone (TIL102-
C4) are shown in Figure 1A, while similar results were CD4 T cells (Figure 2A), and constructed an Ii-fusion
LAGE1 as a Ligand for Treg Cells
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Figure 2. Identification of a cDNA Encoding
LAGE1 by Screening an Ii-cDNA Library of
M102mel
(A) Establishment of 293ECII cells expressing
HLA-DR13 molecules. 293ECIIDR13 cells were
stained with anti-HLA-DR13 or control anti-
bodies. Stained cells were analyzed by FACS.
(B) Identification of a positive cDNA pool (no.
46) capable of stimulating increased secre-
tion of IFN- from CD4 T cells. Optical den-
sity reading at a 450 nm wavelength revealed
a single positive well in one of the 96-well
plates.
(C) After rescreening the positive pool, two
individual positive cDNA clones were identi-
fied on the basis of IFN- release from CD4
TIL102-C4 cells. CD4TIL102-C4 cells recog-
nized 293ECIIDR13 cells transfected with
cDNA clones 2 and 3, but not with a control
cDNA clone 1 or GFP.
(D) Recognition of both Ii fusion LAGE1 and
the naive form of LAGE1 by T cells. 293ECI-
IDR13 cells were transfected with pIi-LAGE1,
LAGE1, or NY-ESO-1 cDNA. T cell recognition
was determined on the basis of IFN- release
from CD4 TIL102-C4 cells.
cDNA library using mRNA isolated from M102 tumor containing 293ECIIDR13 cells transfected with LAGE1
or NY-ESO-1, and to wells seeded with M102 tumorcells. The quality of the cDNA library was evaluated by
determining the size and percentage of cDNA inserts. cells. Following overnight incubation, IFN- release was
determined from cell supernatants. As expected, all 13DNA library pools were prepared in 96-well format plates
and were transfected into 293ECIIDR13 cells. After of the T cell clones recognized M102 tumor cells, but
none recognized 293ECIIDR13 cells transfected withscreening the Ii-fusion cDNA library, we identified a posi-
tive pool that stimulated T cells for increased IFN- re- NY-ESO-1 (Figure 3A). By contrast, 10 of the 13 CD4
T cell clones recognized LAGE1. These studies suggestlease (Figure 2B). The positive-pool DNA was then trans-
formed into E. coli, and individual colonies were picked that while the majority of tumor-reactive T cell clones
recognize LAGE1 as the DR-13-restricted antigen, threefor preparation of plasmid DNA. After rescreening of
individual plasmid DNAs, we identified single cDNA T cell clones (numbers 3, 8, and 13) may recognize other
unidentified tumor antigens presented by DR13 mole-clones that could stimulate T cells for cytokine release.
Figure 2C shows that cDNA clones 2 and 3 were capable cules. These data also imply that the ligand for TIL102-
C4 T cells resides in a region of LAGE1 with differentof stimulating T cells, while cDNA clone 1 failed to acti-
vate T cells for the secretion of IFN-. DNA sequence amino acid sequences from NY-ESO-1.
To identify T cell epitopes from LAGE1, we made twoanalysis and database searches revealed that both posi-
tive cDNA clones encoded the LAGE1 protein, which 13-mer peptides based on the DR13 peptide binding
motif as well as amino acid differences between LAGE1shares 94% nucleotide sequence identity with NY-
ESO-1 (Chen et al., 1997; Wang et al., 1998). LAGE1 was and NY-ESO-1, and tested their ability to stimulate
T cells. Figure 3B shows that TIL102-C4 T cells recog-initially suggested as a tumor antigen on the basis of
representational difference analysis (Lethe et al., 1998), nized 293ECIIDR13 cells pulsed with LAGE-P108-120, but
not with a control peptide, LAGE-P125-137, containing thebut MHC class II-restricted T cell epitopes from this 180
amino acid protein have not been reported. Like NY- HLA-DR13 peptide binding motif. T cell stimulation was
observed at a peptide concentration of 0.1 M for sevenESO-1, LAGE1 is expressed in cancer cells and normal
testis, but not in other human normal tissues. When T cell clones tested (Figure 3C). While TIL102-C4 and
C7 T cells showed a slightly low activity, other T celltested for their ability to recognize LAGE1 and NY-
ESO-1, TIL102-C4 T cells responded to LAGE1-express- clones exhibited similar activity and affinity for the
LAGE-P108-120 peptide.ing HEK293ECIIDR13 cells, but not those expressing
NY-ESO-1 (Figure 2D). Moreover, T cells recognized
both the native and Ii-targeted forms of LAGE1, sug- TCR Usage and Cytokine Profiles of CD4
T Cell Clonesgesting that the native form of LAGE1 is naturally pro-
cessed and presented by HLA-DR13 molecules to We next sought to determine whether all LAGE1-specific
T cell clones are the same or different clones. Twenty-CD4 T cells.
five pairs of TCR-V-specific primers were synthesized
and used for RT-PCR amplification of RNAs isolatedIdentification of the T Cell Ligand/Epitope from LAGE1
To determine the proportion of T cell clones derived from each T cell clone (McKee et al., 2000). We found
that TIL102-C1, -C2, -C4, and -C7 T cell clones sharedfrom TIL102 that recognize NY-ESO-1 and/or LAGE1,
we transfected LAGE1 and NY-ESO-1 into 293ECIIDR13 the same TCR-V7 gene, while TIL102-C6 and TIL102-
C12 shared the same TCR-V6 gene. TIL102-C9, -C10,cells. We added the T cell clones individually to wells
Immunity
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Figure 3. Identification of a T Cell Ligand for CD4 TIL102 T Cell Clones
(A) T cell recognition of LAGE1 presented by HLA-DR13 molecules. 293ECIIDR13 cells were transfected with LAGE1 or NY-ESO-1 cDNA.
Thirteen T cell clones derived from TIL102 bulk T cell line were added to determine their ability to recognize LAGE1 or NY-ESO-1. M102 tumor
cells were used as a positive control for T cell recognition. Ten of thirteen T cell clones recognized LAGE1 and tumor cells. Three recognized
tumor cells, but not 293ECIIDR13 cells transfected with either LAGE1 or NY-ESO-1.
(B) Identification of a peptide recognized by T cell clones. TIL102-C4 responded to the LAGE-P108-120 peptide, but not to the LAGE-P125-137
control peptide.
(C) Titration of peptide concentrations for T cell recognition. To determine peptide concentrations required for T cell recognition, 293ECIIDR13
cells were incubated with different concentrations of the LAGE-P108-120 peptide for 90 min and then washed three times with T cell assay
medium. T cells from seven different T cell clones were added to peptide-pulsed 293ECIIDR13 cells overnight. IFN- release from T cells was
determined with an ELISA kit. Similar results were obtained in three repeated experiments.
and -C11 T cells may differ in their TCR-V usage be- TGF-, while TIL102-C10 cells secreted GM-CSF, IFN-,
and IL-10, but little or no IL-2, IL-4, or TGF-. To comparecause we failed to amplify any distinct band using 25
pairs of primers specific for V genes, while the constant this profile with results for other CD4effector T cells, we
generated antigen-specific CD4 T cell clones (TIL1363-region was successfully amplified (data not shown).
TIL102-C5 contained bands of V6 and V7 genes, sug- C1 and -C2) from TIL1363 that recognized a fusion tumor
antigen, LDFP (Wang et al., 1999b). We found thatgesting that it represents a mixture of two T cell clones.
Representative data from three T cell clones are shown TIL1363-C1 and -C2 CD4 T cell clones secreted IL-2,
GM-CSF, and IFN-, but no other cytokines after stimu-in Figure 4A. The results of TCR profiling analysis led
us to select TIL102-C4, -C6, and -C10 as representative lation with the 1363mel target cells (Figure 4B). An anti-
gen-unspecific CD4-C5 clone derived from PBMCs ofT cell clones for further analysis.
To evaluate the secretion of IL-2, IL-4, IL-10, IFN-, a normal donor did not respond to a tumor mixture of
M102 and 1363mel cells, and served as a specificityand TGF- by T cell clones, we measured cytokine re-
lease from T cell clones after coculturing with HLA- control.
DR13-positive EBV-B or 293ECIIDR13 cells pulsed with
the LAGE1-P108-120 peptide for 18 hr. Representative data CD4 T Cell Clones Phenotypically Resemble
CD4 Treg Cellsfrom TIL102-C4, -C6, and -C10 T cell clones are shown
in Figure 4B. TIL102-C4 and -C6 T cells both secreted The cytokine release profile of TIL102 CD4 T cell clones
suggested that they may represent CD4 Treg cellsGM-CSF, IFN-, IL-4, and IL-10, but little or no IL-2 or
LAGE1 as a Ligand for Treg Cells
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Figure 4. Characterization of Tumor-Reactive CD4 TIL102 T Cells
(A) Clonality of tumor-reactive TIL102 T cell clones by TCR profiling analysis. Total RNAs were isolated from individual TIL102 T cell clones
and analyzed by RT-PCR using 25 pairs of V chain-specific primers. The primers for the constant region V chain were used as positive
controls. Specific DNA bands amplified by PCR indicate the usage of TCR V chains by TIL102 T cell clones and the purity of T cell clones.
(B) Cytokine profiles of CD4 TIL102-C4, -C6, and -C10 T cells. GM-CSF, IFN-, IL-2, IL-4, IL-10, and TGF- were determined from cell culture
supernatants of T cells after coculturing with their corresponding tumor cells. TIL-1363-C1 and -C2 T cell clones were used as representatives
of cytokine profiles of typical CD4 effector (Th1) T cells. CD4-C5 T cells derived from human PBMCs were not antigen specific and served
as a specificity control. Bars with 1000 pg/ml indicate that optical readings at 450 nm were higher than that of the highest level of standards
(1000 pg/ml).
rather than CD4 T helper cells. To test this possibility, C5 T control grown in the same condition expressed
few if any CD25 or GITR molecules. When intracellularwe first examined the phenotypes of CD4 TIL102
clones together with a control CD4 T cell clone (CD4- stained T cells with an antibody against CTLA4, all T cell
clones were uniformly positive, but no appreciable dif-C5) by FACS analysis. Figure 5A shows that CD4TIL102
clones were positive for CD4, CD25, and GITR markers ferences were noted among T cell clones (data not
shown). Further testing of the expression levels of CD25more than 1 month after T cell expansion, while the CD4-
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Figure 5. Phenotypic and Foxp3 Expression Analyses of CD4 TIL102 Treg Cells
(A) CD4 TIL102 Treg cells and a control CD4 T cell clones from human PBMCs were stained with phycoerythrin (PE)- or FITC-labeled mAbs
to CD4, CD25, and GITR molecules. An isotype antibody served as the control. All three clones of TIL102-C4, -C6, and -C10 Treg cells
expressed high levels of CD4, CD25, and GITR molecules, while the control CD4-C5 T cells expressed low levels of CD25 and GITR. All FACS
analyses were conducted at more than 1 month after T cell expansion.
(B) Expression of CD4, CD25, and GITR molecules by antigen-specific TIL1363-C1 and -C2 T cells 2 weeks after T cell expansion.
(C) Foxp3 expression by TIL102 Treg cells and antigen-specific effector/control T cells. cDNA from each T cell clone was subjected to real-
time quantitative PCR analysis using primers and an internal fluorescent probe for Foxp3 or HPRT (hypoxanthine-guanine phosphoribosyl-
transferase). The relative quantity of Foxp3 in each T cell sample was normalized to the relative quantity of HPRT. Foxp3 expression levels
in TIL102-C4, -C6, and -C10 were much higher than those in TIL1363-C1, -C2, and CD4-C5 T cells. (A) through (C) each represent one of
three independent experiments.
and GITR markers in antigen-specific TIL1363-C1 and Recently, the forkhead transcription factor Foxp3 was
shown to be specifically expressed by CD4 Treg cells,-C2 T cells demonstrated that like CD4-C5, these CD4
effector T cells were negative for CD25 and GITR mole- thus affording a reliable marker for these cells (Fontenot
et al., 2003; Hori et al., 2003; Khattri et al., 2003). Compar-cules (Figure 5B). All T cell clones were maintained in
the same condition and growth medium containing a ison of Foxp3 expression levels among tumor-specific
CD4 TIL102 T cell clones revealed much higher levelslow level of IL-2 after expansion. Thus, it appears that
the CD4 TIL102-C4, -C6, and -C10 T cells express the of Foxp3 mRNA (10-fold or more) in CD4 TIL102-C4,
-C6, and -C10 T cell clones than in CD4 TIL1363 andmarkers typically found on naturally occurring CD4
CD25 Treg cells (Shevach, 2002; Wood and Sakaguchi, CD4-C5 T cell clones (Figure 5C). These results indicate
that these antigen-specific CD4 TIL102 T cells are2003), while TIL1363 CD4 T cell clones display the
markers of T helper cells. CD4 Treg cells.
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CD4 T Cell Clones Suppress the Proliferative TIL102-C4 Treg cells in the presence or absence of IL-2,
suggesting that exogenous IL-2 could not reverse theActivity of CD4 T Cells
Definitive evidence of CD4 Treg cells ultimately resides suppressive effect of TIL102-C4 Treg cells on the prolif-
erative response of responding CD4 T cells.in the demonstration of their ability to suppress the pro-
liferation of naive CD4 T cells in functional assays (von
Herrath and Harrison, 2003). Hence, we purified naive Cell-Cell Contact Is Required for Suppressive
CD4 T cells from human PBMCs as responding T cells Activity by CD4 Treg Cells
and cocultured them with CD4 TIL102-C4, -C6, -C10, We next tested how CD4 TIL102 Treg cells inhibit other
or TIL1363 T cell clones in growth medium containing CD4 effector T cells. Several mechanisms have been
purified APCs and anti-CD3 antibody. As shown in Fig- proposed to explain how CD4 Treg cells inhibit CD4
ure 6A, the CD4 TIL102-C4, -C6, and -C10 T cells pos- effector T cells (Shevach, 2002). Some authors suggest
sessed only scant proliferative activity, whereas naive that IL-10 and/or TGF- are directly involved in T cell-
CD4 T cells proliferated activity strongly after stimula- mediated suppression, while others contend that cell-
tion with the anti-CD3 antibody. When cocultured with cell contact is required for suppression (Levings et al.,
the purified CD4 T cells, CD4 TIL102 T cell clones 2002a; Shevach, 2002). These discrepancies may reflect
significantly suppressed anti-CD3-induced proliferation the use of different systems or different CD4 Treg cell
in a dose-dependent manner. By contrast, we did not populations in these studies. We examined these possi-
observe any suppressive activity by CD4 TIL1363 and bilities by studying tumor-specific CD4 Treg cells in
a control CD4 T cell clone (Figure 6A), both of which the presence of various antibodies against human IL-
enhanced the proliferative activity of naive CD4 T cells. 10 or TGF- molecules. As shown in Figure 7A, neither
Taken together, these results indicate that these tumor- anti-IL-10 nor anti-TGF- antibody, nor both molecules
specific CD4 TIL102 T cell clones can be functionally together, could block the suppressive effect of CD4
classified as CD4 Treg cells. TIL102-C4 Treg cells on naive CD4 T cells.
To test whether cell-cell contact is required for CD4
TIL102-C4 Treg cells to exert their suppressive activity,Suppressive Activity of TIL102 Treg Cells Requires
we performed transwell experiments. We first did cocul-Ligand-Specific Activation
ture experiments using the same Treg cell clonesWe next addressed the question of whether suppressive
(TIL102-C4, -C6, and -C10 clones) in parallel to makeeffect of CD4 regulatory TIL102 T cell clones on CD4
sure that these T cells possessed functional suppressiveeffector TIL1363-C1 requires ligand-specific activation.
activity. As shown in Figure 7B, when CD4 TIL102-C4,CD4 Treg cells (TIL102-C4, -C6, and -C10 T cells) were
-C6, and -C10 Treg cell clones were cultured togethercocultured with CD4 effector TIL1363-C1 cells in the pres-
(1:1 ratio) with the naive CD4 T cells in the presenceence of the LAGE-P108-120 peptide-pulsed 293ECIIDR13
of anti-CD3 and the purified APCs, they inhibited thecells. IL-2 secretion from TIL1363-C1 was determined
proliferative activity of the naive CD4 T cells. CD4-after exposure to 1363mel cells. As a control, we co-
C5 T cells, by contrast, lacked the ability to inhibit thecultured TIL102 CD4 Treg cells with CD4 effector
proliferative response of the naive CD4 T cells to anti-TIL1363-C1 in the presence of the LAGE-P125-137 control
CD3 antibody stimulation, regardless of the coculturingpeptide-pulsed 293ECIIDR13 cells to determine the
or transwell conditions. However, in transwell experi-specificity and requirement for inhibition mediated by
ments, CD4 TIL102-C4, -C6, and -C10 Treg cells, whenTIL102-C4, -C6, and -C10 T cells. As shown in Figure 6B,
cultured in the inner well containing medium with anti-IL-2 secretion by TIL1363-C1 T cells was not inhibited by
CD3 and the purified APCs, did not proliferate by them-CD4 regulatory TIL102 T cells in the presence of the
selves and did not inhibit the proliferative activity ofLAGE-P125-137 control peptide. However, the ability of
CD4 naive T cells cultured in the outer well containingTIL1363-C1 T cells to secrete IL-2 was completely sup-
the same medium with anti-CD3 and the purified APCspressed by CD4 TIL102-C4, -C6, and -C10 Treg cells
(Figure 7B). These results demonstrate that cell-cell con-activated by the LAGE-P108-120 peptide. These data pro-
tact is required for the T cell-mediated suppressive ac-vide compelling evidence that suppressive activity of
tivity of CD4 Treg cells.CD4 TIL102 Treg cells requires ligand-specific activa-
tion. Because HLA-DR1-restricted TIL1363-C1 cells rec-
ognized an LDFP antigen on 1363mel cells (Wang et al., Discussion
1999b), but not 293ECIIDR13/the LAGE-P108-120 peptide,
while CD4 Treg cells recognized 293ECIIDR13/the In this study we demonstrate that antigen-specific CD4
Treg cell clones can be established from the TILs ofLAGE-P108-120 peptide, but not 1363mel cells, we con-
clude that recognition of antigens on the same APCs patients with cancer by the limiting dilution method.
After expansion in vitro, these T cells maintained theirby CD4 TIL102 Treg cells and effector T cells is not
required for CD4 TIL102 Treg cells to exert its inhibitory antigen specificity and suppressive function, most likely
reflecting their tumor recognition and suppressive prop-effect. Thus, once activated, these CD4 Treg cells can
inhibit other CD4 effector cells. erties in vivo. Other studies have also shown increased
proportions of tumor-associated CD4CD25 Treg cellsTo test whether suppressive activity of CD4 Treg
cells could be reversed by exogenous IL-2, we added in the TILs of patients with cancer (Liyanage et al., 2002;
Woo et al., 2002), but they provided no direct evidence600 IU/ml final concentration of IL-2 to the culture me-
dium during the suppressive assay. As shown in Figure of the antigen specificity of these T cells because of
their reliance on bulk CD4CD25 T cell populations. A6C, there was no difference in suppressive activity of
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Figure 6. Functional Analysis of CD4 TIL102 Treg Cells
(A) Suppressive activity of TIL102 Treg cells. The proliferative activity of freshly prepared CD4 (responding) T cells (1  105) was inhibited
by different numbers of TIL102-C4, -C6, and -C-10 Treg cells in the presence of anti-CD3 antibody. Proliferation of naive CD4 T cells was
assayed by adding [3H]thymidine during the last 12–16 hr of culture. By contrast, CD4 TIL1363-C1 and -C2 effector cells and CD4-C5 T cells
enhanced rather than suppressed the proliferative activity of responding CD4 T cells.
(B) Suppression of the ability of antigen-specific CD4 effector cells to recognize tumor cells by CD4 TIL102 Treg cell clones. CD4 TIL1363-
C1 T cells were coincubated with TIL102-C4, -C6, and -C10 cells, respectively, in the presence of LAGE-P108-120 or LAGE-P125-137 control peptides.
Inhibition of the ability of TIL1363-C1 effector cells in response to 1363mel cells was determined by measuring IL-2 secretion after 18 hr
coculture. TIL102-C4, -C6, and -C10 cells did not affect the ability of TIL1363-C1 to respond to 1363mel cells in the presence of a control
peptide. By contrast, these CD4 Treg cell clones activated by the LAGE-P108-120 peptide resulted in complete inhibition of the ability of 1363-
C1 effector T cells to secret IL-2. Results in (A) and (B) are representative of three independent experiments.
(C) Exogenous IL-2 could not reverse the suppressive activity of TIL102-C4 Treg cells. Responding CD4 T cells were cocultured with TIL102-
C4 Treg cells (1  105) in the presence or absence of exogenous IL-2 (600 IU/ml). Suppressive assays were performed as above. TIL1558-C1
cells served as a control for effector T cells.
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Figure 7. Cell-Cell Contact Is Required for T
Cell Suppression by TIL102 Treg Cells
(A) Anti-IL-10, anti-TGF-, or both antibodies
failed to block the suppressive activity of
TIL102-C6 Treg cells. The suppression of pro-
liferative activity was conducted in the pres-
ence of anti-IL-10, anti-TGF-, or both anti-
bodies. The culture conditions were identical
to that in Figure 6 except for the addition of
antibodies to the culture.
(B) Cell-cell contact is required for T cell sup-
pression. Equal numbers of CD4 responding
T cells were cultured in outer wells; TIL102
Treg T cells or CD4-C5 T cells were cultured
in inner wells. Otherwise, culture conditions
were identical between the inner and outer
wells. To ensure that the TIL102 T cells used
had suppressive activity, we used the cocul-
ture system as our positive control for the
suppressive activity of TIL102 Treg cells.
Once the cells were separated with the re-
sponding CD4 T cells in the transwell sys-
tem, there was no detectable suppressive ac-
tivity of the responding CD4 T cells in the
outer wells, regardless of the presence of
TIL102 Treg, CD4-C5 T cells, or none in the
inner wells. Results represent one of three
independent experiments.
recent report demonstrated the generation of CD4CD25 do not produce effector cytokines during short-term cul-
ture in vitro, while all the LAGE1-specific clones pro-Treg clones from human PBMCs, but their antigen speci-
ficity was not defined (Levings et al., 2002b). Hence, duced large amounts of IFN-, IL-10, and IL-4 (Figure
4). The cellular origin of these regulatory T cell clonesthe CD4 T cell clones presented here are true tumor-
specific CD4 Treg cells. will therefore require further study. It is even possible
that these clones were generated from CD25 T cellsTumor antigen-specific regulatory T cell clones that
we have isolated possess an unusual phenotype. In in vivo following interaction with naturally occurring
CD4CD25 T cells as previously described in vitromany respects they resemble the Tr1 clones described
by Roncarolo et al. in that they secrete both IFN- and (Dieckmann et al., 2002; Jonuleit et al., 2002). Regardless
of the origin of these CD4 Treg cell clones, they func-IL-10 (Groux et al., 1997). On the other hand, they sup-
press activation of naive T cells by a cell contact-depen- tionally suppressed the proliferation and IL-2 secretion
of CD4 effector cells (Figure 6).dent mechanism and express FoxP3, thus resembling
CD4CD25 naturally occurring suppressor cells (Wood Very little information is available on the target antigen
recognized by naturally occurring CD4CD25 T cells.and Sakaguchi, 2003). Another striking feature of these
clones is that they maintained high level expression of Most studies in humans and experimental animals have
focused on bulk CD4 Treg cells, which may displayCD25 and GITR when cultured in medium containing a
low level of IL-2, in contrast to effector type clones very diverse specificity. Our results suggest that it is
essential to generate antigen-specific CD4 Treg clones/cultured in the same condition which downregulated
expression of these antigens (Figure 5). The biological lines as the first step for the identification of the target
ligands for CD4 Treg cells. This strategy should besignificance of this observation is not clear, as very little
data are available on the regulation of GITR expression applied to identification of ligands for antigen-specific
CD4 Treg cells derived from autoimmune diseases ason human CD4 T cells during the course of T cell activa-
tion. Furthermore, naturally occurring CD4CD25 cells well as the infected hosts. Although CD4 effector T cells
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T Cell Cloning and Expansionmight recognize the same LAGE1 T cell epitope as CD4
T cell clones were generated from TIL102 and TIL1359 by limitingTreg cells, several CD4 T cell clones we generated
dilution methods (at 0.3 cell/well) as previously described (Wang etwere exclusively CD4 Treg cells. LAGE1 belongs to
al., 2002). On day 0, T cells were stimulated in RPMI1640 medium
an expanding list of cancer-testis antigens, which are containing anti-CD3 antibody (30 ng/ml) and 5  104 allogeneic
expressed in cancer cells and normal testis, but not in peripheral blood mononuclear cells (PBMCs) as feeder cells and
10% human AB sera. On day 1, 300 IU/ml of IL-2 was added. Cultureother normal tissues (Lethe et al., 1998). While T cell
medium was changed every 3 days with fresh RPMI 1640 mediumepitopes have been identified from the CAMEL (an alter-
containing 10% human AB sera, glutamine, -mercaptoethnol, andnative open reading frame) (Mandic et al., 2003; Slager
300 IU/ml of IL-2. On day 14, T cell clones were picked and testedet al., 2003), CD4 T cell ligand within the LAGE1 primary
for their activities against M102 tumor cells. T cells in the absence
open reading frame identified in this study has not been of tumor cells served as a control. To obtain optimal expansion, we
reported. Its identification as a natural ligand for CD4 used the OKT3 expansion method as previously described (Wang
et al., 1999a). T cell clones were maintained at a low IL-2 concentra-Treg cells is of particular interest because many tumor
tion (30 IU/ml). Melanoma cell lines and EBV-transformed B cellimmunologists believe that cancer-testis antigens are
lines used in this study were cultured in RPMI 1640 medium con-ideal targets for cancer immunotherapy. However, our
taining 10% FCS. 293ECIIDR13 cells were established by transfect-data show that ligand-specific activation of CD4 Treg
ing plasmid DNA encoding DRB1*1301 cDNA into 293ECII cells as
cells is required for subsequent suppressive effect on described (Wang et al., 1999a) and were selected with RPMI 1640/
other effector cells (Figure 6B), suggesting that tumor- 10% FCS containing Zeocin (250 g/ml). HLA-DR13-positive cells
were sorted by FACS after staining with anti-HLA-DR13-specific an-specific, nonmutated self-antigens such as LAGE1 may
tibodies.stimulate and expand CD4 Treg cells at the tumor sites,
thus inducing immune tolerance.
cDNA Library ConstructionThis prediction appears relevant to the results of re-
Total RNA was extracted from M102 cells using Trizol reagent (In-cent clinical trials using MHC class I-restricted tumor
vitrogen, Inc., San Diego, CA). Poly(A) RNA was purified from total
antigens. Although some evidence for a therapeutic ef- RNA by the polyATract system (Promega, Madison, WI) and con-
fect on tumor growth was obtained in these studies, verted to cDNA using a cDNA construction kit (GIBCO BRL) with an
oligo-dT primer. The cDNA inserts were then ligated to a pTSXimmune responses were weak and transient in most
vector containing an Ii fragment (amino acids 1–80) (Wang et al.,vaccinated patients. Among the many factors that may
1999a), and cDNA libraries were electroporated into DH10B cells.have contributed to this failure, the presence of tumor-
Plasmid DNA for cDNA library pools was prepared from bacteria,specific CD4 Treg cells at tumor sites could have
each consisting of approximately 100 cDNA clones.
played a significant role in the suppression of antitumor
immunity. Indeed, the removal of CD4CD25 T cells Screening of cDNA Library
by an anti-CD25 antibody in animal models enhanced DNA transfection and GM-CSF assays were performed as previously
described (Wang et al., 1999a). In brief, 200 ng of cDNA pools wereantitumor responses (Sakaguchi et al., 2001; Sutmuller
mixed with 2 l of Lipofectamine in 100 l of serum-free DMEM foret al., 2001). These observations suggest that the suc-
15–45 min. The DNA/Lipofectamine mixture was then added to thecess of peptide-based immunotherapy for cancer and
293ECIIDR13 cells (5  104) and incubated overnight. The following
autoimmune diseases may ultimately depend on the day, cells were washed twice with AIM-V medium. CD4 T cells
balance between regulatory and effector T cells (Powrie were then added at a concentration of 5  104 cells/well in AIM-V
and Maloy, 2003). New strategies that simultaneously medium containing 120 IU/ml of IL-2. After 18–24 hr of incubation,
100 l of supernatant was collected and IFN- concentrations werestimulate CD4 effector T cells while inhibiting or deplet-
measured in a standard ELISA assay.ing CD4 Treg cells are therefore needed to shift this
dynamic equilibrium toward effector T cells in the treat-
Peptides Synthesis and T Cell Epitopesment of cancer patients. The opposite approach, fa-
The peptides were synthesized by a solid-phase method using a
voring expansion of the CD4 Treg population, might peptide synthesizer (Model AMS 422, Gilson Co., Inc., Worthington,
improve the treatment of autoimmune diseases. OH). Some peptides were purified by HPLC and had greater than
In summary, we have generated and characterized 98% purity. The mass of some peptides was confirmed by mass
spectrometry analysis. Peptides reactive with CD4 T cells weretumor-specific CD4 T cell clones derived from the TILs
identified and characterized as previously described (Wang et al.,of a melanoma patient. Their phenotypic and functional
1999a).properties were indicative of antigen-specific CD4Treg
cells, and they recognized LAGE1 peptide as a natural
FACS Analysis
ligand. Cell-cell contact was required for T cell-mediated Expression of GITR was determined after staining T cells with an
immune suppression, but other aspects of the molecular anti-GITR antibody (R&D Systems) followed by a secondary goat
mechanism remain to be defined in future studies. Such anti-mouse mAb conjugated to FITC. T cells were maintained in the
culture medium containing a low IL-2 (30 IU/ml) for at least 2 weeksinformation should open opportunities for the manipula-
before FACS analysis. Analysis of the expression of intracellulartion of antigen-specific immune responses directed to
CTLA-4 was performed as previously described (Shimizu et al.,cancer as well as autoimmune and infectious diseases.
2002). To determine the expression of CD4, CD25, CCR5, CCR7,
and CD45RA, we stained T cells with the respective antibodies (BD
Biosciences) conjugated to either PE or FITC. After washing, cellsExperimental Procedures
were analyzed by FACSscan.
Cell Lines
CD4 tumor-infiltrating lymphocytes (TIL102) were cultured from a Antibody Blocking and Cytokine Release Assays
To determine whether T cell recognition could be blocked by specificfresh tumor sample surgically removed from a melanoma patient.
All TILs and T cell clones were grown in RPMI 1640 medium con- antibodies, we measured T cell activity in the absence or presence
of various antibodies, as previously described (Wang et al., 1999a).taining 10% human AB serum and recombinant IL-2 (300 IU/ml).
Melanoma cell lines and Epstein-Barr virus (EBV)-transformed B cell These antibodies, including L243 (anti-HLA-DR; HB55), IVA12 (anti-
HLA-DR, -DP, -DQ; HB145), IVD12 (anti-HLA-DQ, -DR; HB144), andlines were maintained in RPMI 1640 with 10% fetal calf serum (FCS).
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W6/ 32 (HLA-A, -B, -C; HB95), were purified from American Type Lee and many pathologists at the UT MD Anderson Cancer Center
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IL-2, IL-4, IL-10, IFN-, and TGF- release from T cells was measured R.-F.W.
in culture supernatants by ELISA kits (Pierce, Rockford, IL).
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